Google
Trusted Resources: News & Events
Latest announcements and gatherings
Novartis acquires US pharma research firm Selexys Pharmaceuticals
Swiss-based pharmaceuticals giant Novartis said Monday it was acquiring Selexys Pharmaceuticals Corp., a US research lab in blood and inflammatory disorders, in a deal costing up to $665 million (627 million euros).
Selexys specialises in sickle cell disease, an inherited form of anaemia that is most common among people of African descent.
In a statement, Novartis said it exercised rights to buy the company after seeing results from a large trial into a drug to treat pain for people with the disease.
+myBinderRelated Content
-
Sickle Cell Disease: A Review of Nonpharmacological Approaches for PainCONTEXT: Sickle cell disease (SCD) is a...
-
Management of male fertility in sickle cell disease before and after hydroxycarbamideHydroxycarbamide (hydroxyurea or HU) is ...
-
Progress in pursuit of sickle cell cureBao, in collaboration with Baylor Colleg...
-
BCL11A-based gene therapy for sickle cell disease passes key preclinical testA precision-engineered gene therapy viru...
-
MaxCyte and U.S. National Institutes of Health’s National Heart, Lung, and Blood Institute enter cooperative r...MaxCyte, Inc. today announces it has e...
-
Improving the Lives of People with Sickle Cell Diseasehttps://www.youtube.com/watch?v=NPaV0glX...
-
Voxelotor can Promote Long-Term Benefits in Teens, Adults With SCD, Latest Clinical Data ShowGlobal Blood Therapeutics’ lead therap...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.